Abstract:These results suggest that there is no absolute barrier to pig hematopoietic cell engraftment in primates, and that this may be facilitated if the return of anti-Gal IgG can be prevented.
“…Subsequent studies attempted to increase engraftment by raising the dose of progenitor cells administered through the use of cytokine-mobilized PBPC, achieving doses as high as 2–4 × 10 10 cells/kg following mobilization and pheresis [62,63]. Even after administration of these enormous doses of pig cells, they were generally detected in the baboon circulation for only 2–5 days, although one animal demonstrated a second appearance of pig cells in the circulation on days 16–21 [64].…”
Section: Current Status Of Tolerance Induction In Primatesmentioning
Because the immunologic differences between species are far greater than those within species, it is likely that the amount of immunosuppression that would be required for successful xenografting would be so much greater than that now used for allografting, that the side-effects and complications would be unacceptable. Tolerance approaches to xenotransplantation would overcome this concern. Studies in humanized mouse models have demonstrated that human T cells can be tolerized to porcine xenografts, providing important proofs of principle of the potential feasibility of pig-to-primate xenograft tolerance. The results available from studies of pig-to-primate xenotransplantation to date have demonstrated that while chronic immunosuppressive drugs have not completely avoided either T cell responses or humoral rejection, approaches directed toward tolerance induction have been encouraging with regard to avoiding immunization at both of these levels.
“…Subsequent studies attempted to increase engraftment by raising the dose of progenitor cells administered through the use of cytokine-mobilized PBPC, achieving doses as high as 2–4 × 10 10 cells/kg following mobilization and pheresis [62,63]. Even after administration of these enormous doses of pig cells, they were generally detected in the baboon circulation for only 2–5 days, although one animal demonstrated a second appearance of pig cells in the circulation on days 16–21 [64].…”
Section: Current Status Of Tolerance Induction In Primatesmentioning
Because the immunologic differences between species are far greater than those within species, it is likely that the amount of immunosuppression that would be required for successful xenografting would be so much greater than that now used for allografting, that the side-effects and complications would be unacceptable. Tolerance approaches to xenotransplantation would overcome this concern. Studies in humanized mouse models have demonstrated that human T cells can be tolerized to porcine xenografts, providing important proofs of principle of the potential feasibility of pig-to-primate xenograft tolerance. The results available from studies of pig-to-primate xenotransplantation to date have demonstrated that while chronic immunosuppressive drugs have not completely avoided either T cell responses or humoral rejection, approaches directed toward tolerance induction have been encouraging with regard to avoiding immunization at both of these levels.
“…Newly developing B cells could not be found in spleens of late chimeras, suggesting deletion and/or receptor editing [117]. Still, engraftment barriers across species are difficult and might be overcome via retroviral gene therapy [104, 118]. …”
Section: A Future For Molecular Chimerism or Xenograft Tolerance?mentioning
Organ transplant recipients require life-long treatment with immunosuppressive drugs. Currently available immunosuppression is associated with substantial morbidity and mortality, and is ineffective in inhibiting chronic rejection and graft loss. Therefore, a permanent state of donor-specific tolerance remains a primary goal for transplantation research. The induction of mixed hematopoietic chimerism is an attractive concept in this regard. Hematopoietic chimerism modulates the immunologic repertoire by extending the mechanisms of self-tolerance to donor-specific allotolerance. Despite recent progress in developing nontoxic bone marrow transplantation protocols for rodents, translation to large animals has remained difficult. Here, we outline the concept of tolerance via mixed chimerism, and review recent progress and remaining challenges in bringing this approach to the clinical setting.
“…[12][13][14] Based on experience of allotransplantation across the ABO blood group barrier (reviewed in Ref 15), particularly by Alexandre and colleagues, 16 in which depletion of Abs at the time of the organ transplant resulted in accommodation (graft survival in the presence of specific anti-donor Ab and complement), enormous efforts were expended to achieve accommodation by the initial immunoadsorption of anti-Gal Abs using immunoaffinity columns of various Gal-glycoconjugates. [17][18][19][20][21][22][23][24][25] Although anti-Gal Ab could be depleted completely by a course of plasmapheresis and immunoadsorption over the period of a few days, and although this protected the graft from HAR, return of preformed and/or elicited Ab inevitably led to AHXR (Table 2 and Figure 3). 19,22,26 Despite pharmacologic immunosuppressive therapy, graft survival could not be extended beyond 30 days.…”
Section: Phase Iii: Extracorporeal Immunoadsorption Using Synthetic Gmentioning
confidence: 99%
“…Less morbidity was reported when co-stimulatory blockade was introduced. 21, 24,39 The fact that anti-non-Gal Abs were not adsorbed may have been detrimental, as subsequent in vitro laboratory studies have indicated that anti-non-Gal Abs can result in pig cell lysis. 41 It has recently been demonstrated that anti-non-Gal Abs can be associated with AHXR.…”
Section: Phase V: Continuous "Depletion" or "Neutralization" Of Anti-mentioning
confidence: 99%
“…21,22,26 The introduction of co-stimulatory blockade allowed prevention of a T-cell-dependent elicited Ab response without the morbidity associated with intensive pharmacologic immunosuppressive therapy. Buhler et al 21,24 and Knosalla et al 45,46 administered anti-CD154 monoclonal Abs (in combination with MMF and corticosteroids) in a pig-hematopoietic-progenitor-cell-tobaboon transplantation model, and demonstrated the efficacy of this agent. Confirmation was demonstrated in a solid-organ transplant model, but again was limited by the continuing effect of pre-formed Ab (Table 3 and Figure 4).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.